JOHNSON & JOHNSON — Director's Dealing 2023

Feb 16, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: JOHNSON & JOHNSON (JNJ)
CIK: 0000200406
Period of Report: 2023-02-13

Reporting Person: Taubert Jennifer L (EVP, WW Chair, Pharmaceuticals)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-13	Common Stock	A	21422.0000	$0.0000	Acquired	150159.0010	Direct
2023-02-13	Common Stock	F	10569.0000	$162.0100	Disposed	139590.0010	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-13	Employee Stock Options (Right to Buy)	$162.7500	A	64634.0000	Acquired	2033-02-13	Common Stock (64634.0000)	Direct
2023-02-13	Restricted Share Units	$	A	3906.0000	Acquired		Common Stock (3906.0000)	Direct

Footnotes

F1: Represents Common Stock received upon the satisfaction of performance and time-based criteria for Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 10, 2020.

F2: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date.

F3: Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to acquire one share of Common Stock.

F4: The Restricted Share Units vest in three equal annual installments beginning on the first anniversary of the grant date.